6:10 PM
 | 
Jan 07, 2013
 |  BC Extra  |  Company News

Heptares, Cubist in GPCR discovery deal

Heptares Therapeutics Ltd. (Welwyn Garden City, U.K.) and Cubist Pharmaceuticals Inc. (NASDAQ:CBST) partnered to discover and develop compounds against two undisclosed GPCR targets selected by Cubist. For the first...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >